第一作者机构:[1]Leiden Univ, Med Ctr, Leiden, Netherlands;[2]Univ Hosp Essen Ruhr, Essen, Germany;[3]Clin & Matern Suizo Argentina, Buenos Aires, DF, Argentina;[4]Mt Sinai Sch Med, New York, NY USA;[5]RTI Hlth Solut, Durham, NC USA;[6]Beijing Anzhen Hosp, Beijing, Peoples R China;[7]Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA;[8]Boehringer Ingelheim Ltd, Burlington, ON, Canada;[9]Boehringer Ingelheim Int Gmbh, Ingelheim, Germany;[10]Ingelheim Birmingham City Hosp, Birmingham, W Midlands, England
推荐引用方式(GB/T 7714):
Huisman M.,Diener H.,Dubner S.,et al.A PROSPECTIVE GLOBAL REGISTRY ON ORAL ANTITHROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION: GLORIA-AF PHASE III BASELINE CHARACTERISTICS[J].EUROPEAN HEART JOURNAL SUPPLEMENTS.2019,21(E):E113-E113.
APA:
Huisman, M.,Diener, H.,Dubner, S.,Halperin, J.,Rothman, K....&Lip, G..(2019).A PROSPECTIVE GLOBAL REGISTRY ON ORAL ANTITHROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION: GLORIA-AF PHASE III BASELINE CHARACTERISTICS.EUROPEAN HEART JOURNAL SUPPLEMENTS,21,(E)
MLA:
Huisman, M.,et al."A PROSPECTIVE GLOBAL REGISTRY ON ORAL ANTITHROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION: GLORIA-AF PHASE III BASELINE CHARACTERISTICS".EUROPEAN HEART JOURNAL SUPPLEMENTS 21..E(2019):E113-E113